The NCBI indicates that cardiovascular disease often progresses silently but carries significant risks of serious complications, such as heart attacks and strokes, stemming from factors like high blood pressure, diabetes, lipid disorders, obesity, and smoking.
According to the "National STEPS Survey of Non-Communicable Disease Risk Factors in Vietnam" (STEPS 2021), the prevalence of lipid disorders increased from 30.2% (2015) to 44.1% (2021); the prevalence of hypertension rose from 18.9% to 26.2%; and the number of diabetes patients increased by a factor of 1.73. Without early detection of risk factors and effective control, patients face severe complications and the burden of long-term treatment.
In response to this situation, Long Chau pharmacy system and AstraZeneca pharmaceutical company are collaborating to enhance pharmacists' professional capacity through a series of scientific workshops, the HOPE professional update program, within the framework of the "10 Years of Dapagliflozin in Vietnam Journey".
"Through this series of activities, Long Chau pharmacists are more confident in providing disease counseling, encouraging people to understand the important role of regular screening, aiming to prevent early complications for effective management of chronic diseases, especially cardiovascular, renal, and metabolic ones", representatives from both sides said.
 |
Long Chau and AstraZeneca launch the 10-year anniversary campaign of Dapagliflozin in Vietnam (left) and collaborate to implement the HOPE project - supporting Long Chau pharmacists to improve their capacity and accompany patients with chronic diseases. Photo: LC |
Long Chau and AstraZeneca launch the 10-year anniversary campaign of Dapagliflozin in Vietnam (left) and collaborate to implement the HOPE project - supporting Long Chau pharmacists to improve their capacity and accompany patients with chronic diseases. Photo: LC
In addition, Long Chau and AstraZeneca are also implementing a series of communication activities revolving around two main themes: treatment adherence for early heart and kidney protection in type 2 diabetes patients; and dual heart and kidney protection solutions for patients with diabetes and dyslipidemia. The program aims to provide accurate medical information, helping people increase awareness, proactively screen early, and adhere to all treatment regimens.
Currently, some treatment regimens are designed to simultaneously affect multiple mechanisms. For example, the combination of two drug classes, SGLT2i and statins, can control blood sugar and blood lipids while helping to protect the heart and kidneys in the long term.
The "Dual Heart and Kidney Protection Duo" solution is currently available at 2,222 Long Chau pharmacies nationwide. Dapagliflozin and rosuvastatin help delay the need for dialysis by an average of 10.7 years, reduce all-cause mortality by 31%, and slow the progression of atherosclerosis, supporting heart, kidney, and metabolic health for patients with chronic conditions.
 |
Long Chau pharmacy staff participate in a training session to enhance their professional expertise on chronic kidney disease and cardiovascular complications. Photo: LC |
Long Chau pharmacy staff participate in a training session to enhance their professional expertise on chronic kidney disease and cardiovascular complications. Photo: LC
With blood and urine tests, such as uACR, eGFR, and LDL-C, performed periodically at medical facilities with testing services, people can early identify the risk of target organ damage, thereby proactively intervening and effectively managing chronic diseases.
This collaboration plays a crucial role in the journey of creating a sustainable healthcare ecosystem, "for a healthier Vietnam." According to a Long Chau representative: "People have the opportunity to access medical knowledge early and proactively screen their health, not only improving treatment effectiveness and preventing complications, but also contributing to reducing the burden on the national health system."
 |
AstraZeneca and Long Chau offer genuine heart and kidney protection solutions, committed to transparent origin. Photo: LC |
AstraZeneca and Long Chau offer genuine heart and kidney protection solutions, committed to transparent origin. Photo: LC
Representatives of Long Chau and AstraZeneca also committed to continuing their partnership, providing modern and accessible solutions, contributing to building a more proactive and sustainable healthcare system for Vietnamese people.
Dong Ve
